Developer docs
API playgroundTry for free, no card

Search company profiles

PictorLabs

Full company profile

uuid0000ae9

Namestring
PictorLabs
Legal namestring
Pictor Labs, Inc.
Websiteurl
pictorlabs.ai
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Pictor Labs, Inc. is a private, venture-backed digital pathology company founded in 2019 and headquartered in Los Angeles, California. The company develops an AI-powered virtual staining platform that replaces chemical tissue staining with deep learning-based digital alternatives, generating diagnostic-quality virtual stains (H&E, IHC markers such as PanCK and CD45, and special stains including Masson's Trichrome, PAS, and Jones) from unlabeled tissue samples in minutes. The core technology relies on proprietary generative AI models trained on co-registered autofluorescence and brightfield image pairs, eliminating the need for chemical reagents while preserving tissue for downstream molecular and spatial biology workflows. Pathologist validation studies report 99-100% visual comparability to traditional chemical staining.

The product portfolio comprises three core modules: DeepStain (virtual histological staining of label-free tissue), ReStain (computational re-staining of existing H&E images into virtual special stains), and ClearStain (virtual H&E generation for molecular diagnostic and digital sequencing workflows). Pictor offers both cloud-managed and on-premises deployment, with the latter leveraging NVIDIA DGX Spark hardware for in-lab inference. All products are designated Research Use Only and are not FDA cleared for clinical diagnostic use.

The company targets biopharmaceutical companies, contract research organizations, academic medical centers, and veterinary pathology laboratories through an enterprise field sales motion with quote-based pricing. Named customers and collaborators include Charles River, NanoString, Leica Biosystems, University of Maryland, Johns Hopkins, and UCLA. The company has raised approximately $48.8 million across multiple rounds, with a $30 million Series A closed in September 2024 led by Insight Partners and M Ventures. Investors include M Ventures (Merck KGaA's corporate venture arm), SCC Soft Computer, Koç Holding, and Insight Partners.

Short descriptiontext

Pictor Labs develops AI-powered virtual tissue staining software that replaces chemical staining with deep learning-generated diagnostic-quality digital stains for biopharma, CROs, academic medical centers, and veterinary pathology labs. Products are Research Use Only.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, AI virtual staining, computational histology, tissue imaging AI, digital pathology platform
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Digital Pathology Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Virtual Staining Software Licenses/Subscriptions
TypeSubscription Recurring
Description

The company offers its AI-powered virtual staining technology through cloud or on-premises deployment models. Revenue is generated through software licensing and subscription arrangements for access to the virtual staining platform, with deployment configuration determining data processing and storage arrangements.

pictorlabs.ai
2On-Premises Hardware Systems
TypeHardware Sales
Description

On-premises deployment option includes dedicated server or GPU-enabled workstation infrastructure, with Pictor Labs providing software installation packages and updates while customers manage hardware, security controls, and data backups.

pictorlabs.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pictor Labs offers an AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. The platform uses deep learning models trained on co-registered autofluorescence and brightfield images to generate diagnostic-quality virtual stains (H&E, IHC, special stains) from unlabeled tissue samples in minutes, preserving tissue for downstream molecular and multi-modal analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99-100% visual comparability to traditional chemically stained slides
+3 more records
Product overview1 text field

Pictor Labs offers an AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. The platform generates diagnostic-quality virtual stains (H&E, IHC, and special stains) in minutes from unlabeled tissue samples, preserving tissue for downstream molecular and multi-modal analysis. The product portfolio includes DeepStain (virtual histological staining of label-free tissue), ReStain (virtual re-staining of existing H&E images), and ClearStain (virtual H&E for molecular diagnostics workflows). Both On-Premises and Cloud deployment options are available, allowing labs to choose based on data governance requirements. All products are for Research Use Only and are not FDA cleared for clinical diagnostic use.

Product and service6 records
1Pictor Virtual Staining Platform
CategoryDigital Pathology Software
Description

AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. Generates diagnostic-quality virtual stains in minutes from unlabeled tissue samples, preserving tissue for downstream analysis.

2DeepStain
CategoryDigital Pathology Software
Description

Virtual histological staining technology that transforms label-free tissue autofluorescence into rich virtual stains including H&E, IHC markers, and special stains for diverse research workflows.

3ReStain
CategoryDigital Pathology Software
Description

Virtual re-staining capability that applies computational transformations to already-stained H&E tissue images, generating additional stain views (Jones, PAS, Masson's Trichrome) without physical re-staining.

4ClearStain
CategoryDigital Pathology Software
Description

AI-powered virtual H&E solution for molecular diagnostics workflows. Generates virtual H&E images directly from unstained tissue slides, enabling real-time tissue visualization and annotation for downstream molecular testing.

5On-Premises Deployment
CategoryDeployment Option
Description

Local deployment model where virtual staining runs within the customer's own infrastructure using NVIDIA DGX Spark hardware for high-performance AI inference, supporting data privacy requirements and institutional IT security policies.

6Cloud Deployment
CategoryDeployment Option
Description

Cloud-hosted deployment model managed by Pictor Labs offering elastic processing capacity, no local GPU hardware requirement, and centralized access for distributed research workflows.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-01
Description

Technology partnership providing NVIDIA DGX Spark hardware for on-premises AI staining system, enabling high-performance inference for virtual staining tools deployed within pathology labs.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaborative research partnership at SITC 2024 demonstrating multi-modal spatial analysis of classic Hodgkin lymphoma microenvironment utilizing multiplex immunofluorescence and virtual staining. Combines Leica Biosystems' imaging capabilities with Pictor Labs' virtual staining technology for cancer research applications.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Research collaboration for multi-modal spatial analysis of classic Hodgkin lymphoma microenvironment and tumor microenvironment analysis in cancer research. Also collaborated on AI-based computational H&E staining for lymphoma diagnosis study presented at USCAP 2024.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaborative study at USCAP 2024 comparing AI computational H&E staining to chemical staining for lymphoma diagnosis, evaluating alignment between virtual and traditional stains while maintaining pathologist-led interpretation.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaborative study at USCAP 2024 comparing AI computational H&E staining to chemical staining for lymphoma diagnosis, contributing to validation of virtual staining technology for hematopathology research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaborative research presented at AACR 2023 on virtual staining-enabled morphological and spatial transcriptomic analysis of malignant B cells and the tumor microenvironment. Combines Pictor Labs' virtual staining with NanoString's spatial biology platform for advanced tissue analysis.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration for AI-driven virtual staining generating H&E and Fluoro-Jade B images from unstained brain sections, streamlining neuronal degeneration assessment in nonclinical neurotoxicity studies (kainic acid rat model).

Strategic tierStrategicTypeTechnology or Integration
Description

Scanner platform compatibility partnership ensuring Pictor virtual staining integrates with Hamamatsu digital pathology scanners for seamless workflow incorporation.

Strategic tierStrategicTypeTechnology or Integration
Description

Scanner platform compatibility partnership ensuring Pictor virtual staining integrates with Proscia digital pathology platform for seamless workflow incorporation.

Strategic tierStrategicTypeTechnology or Integration
Description

Scanner platform compatibility partnership ensuring Pictor virtual staining integrates with Grundium whole slide imaging systems for seamless workflow incorporation.

Strategic tierStrategicTypeTechnology or Integration
Description

Digital pathology partnership ensuring Pictor virtual staining integrates with pramana imaging solutions for seamless workflow incorporation.

Strategic tierStrategicTypeTechnology or Integration
Description

Digital pathology partnership ensuring Pictor virtual staining integrates with PredxBio spatial biology solutions for multi-modal tissue analysis workflows.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based AI pathology company developing deep-learning models for diagnostic and drug-development applications across biopharma and clinical labs. Direct competitor for biopharma and CRO research budgets and for clinical pathology AI deployment.

TypeDirect peer
Description

AI pathology company with FDA-cleared products for prostate and breast cancer, serving biopharma, hospitals, and reference labs. Comparable in targeting biopharma and clinical pathology customers, with a head start in FDA-cleared diagnostics.

TypeDirect peer
Description

AI-biopharma company with a pathology AI platform used for spatial biology, biomarker discovery, and clinical research, including federated-learning deployment. Comparable in combining AI pathology with biopharma R&D workflows.

TypeDirect peer
Description

Israel-based AI pathology company with multiple CE-IVD and FDA-cleared products deployed across hospital and diagnostic-lab networks. Direct competitor for clinical pathology decision-support deployments and partnerships with scanning platforms.

TypeEmerging player
Description

Netherlands-based AI pathology startup focused on kidney and prostate pathology algorithms for research and clinical use. Comparable in using deep learning to generate diagnostic-quality outputs from pathology images, but narrower in tissue type coverage.

TypeEmerging player
Description

South Korea-based AI pathology company offering deep-learning cancer diagnostic models integrated with major scanner platforms. Comparable in targeting digital pathology workflows and partnering with scanner OEMs, but focused primarily on prostate cancer diagnosis.

TypeEmerging player
Description

Israel-based spatial biology AI company applying deep learning to multiplex tissue imaging for biopharma and clinical research. Comparable in serving the spatial-biology and multi-modal tissue analysis segment of the market, particularly biopharma biomarker discovery.

TypeBroad incumbent
Description

Digital pathology platform company offering Concentriq image management, AI integrations, and computational pathology workflows, including a partnership with Pictor Labs. Comparable as a digital pathology ecosystem player and channel partner, but broader in scope (platform vs. specific staining AI).

TypeBroad incumbent
Description

Japanese manufacturer of whole-slide imaging scanners and a long-standing incumbent in digital pathology hardware. Both a Pictor integration partner and a potential competitive threat if scanner OEMs embed native virtual-staining capabilities.

TypeBroad incumbent
Description

Danaher-owned pathology instruments, staining reagents, and imaging business with broad clinical pathology footprint. Both a Pictor research partner and a potential competitor given internal pathology AI and reagent capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PictorLabs

Digital Pathology Softwarepictorlabs.ai

Pictor Labs develops AI-powered virtual tissue staining software that replaces chemical staining with deep learning-generated diagnostic-quality digital stains for biopharma, CROs, academic medical centers, and veterinary pathology labs. Products are Research Use Only.

What PictorLabs does

Pictor Labs, Inc. is a private, venture-backed digital pathology company founded in 2019 and headquartered in Los Angeles, California. The company develops an AI-powered virtual staining platform that replaces chemical tissue staining with deep learning-based digital alternatives, generating diagnostic-quality virtual stains (H&E, IHC markers such as PanCK and CD45, and special stains including Masson's Trichrome, PAS, and Jones) from unlabeled tissue samples in minutes. The core technology relies on proprietary generative AI models trained on co-registered autofluorescence and brightfield image pairs, eliminating the need for chemical reagents while preserving tissue for downstream molecular and spatial biology workflows. Pathologist validation studies report 99-100% visual comparability to traditional chemical staining.

The product portfolio comprises three core modules: DeepStain (virtual histological staining of label-free tissue), ReStain (computational re-staining of existing H&E images into virtual special stains), and ClearStain (virtual H&E generation for molecular diagnostic and digital sequencing workflows). Pictor offers both cloud-managed and on-premises deployment, with the latter leveraging NVIDIA DGX Spark hardware for in-lab inference. All products are designated Research Use Only and are not FDA cleared for clinical diagnostic use.

The company targets biopharmaceutical companies, contract research organizations, academic medical centers, and veterinary pathology laboratories through an enterprise field sales motion with quote-based pricing. Named customers and collaborators include Charles River, NanoString, Leica Biosystems, University of Maryland, Johns Hopkins, and UCLA. The company has raised approximately $48.8 million across multiple rounds, with a $30 million Series A closed in September 2024 led by Insight Partners and M Ventures. Investors include M Ventures (Merck KGaA's corporate venture arm), SCC Soft Computer, Koç Holding, and Insight Partners.

PictorLabs firmographics

Firmographics
Name
PictorLabs
Legal name
Pictor Labs, Inc.
Website
https://pictorlabs.ai
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Pictor Labs develops AI-powered virtual tissue staining software that replaces chemical staining with deep learning-generated diagnostic-quality digital stains for biopharma, CROs, academic medical centers, and veterinary pathology labs. Products are Research Use Only.
Ownership category
akta.pro rank

PictorLabs industry classification

Industry
Product category
Digital Pathology Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Digital pathology software
  • AI virtual staining
  • Computational histology
  • Tissue imaging AI
  • Digital pathology platform

Where PictorLabs is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PictorLabs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Virtual Staining Software Licenses/Subscriptions: The company offers its AI-powered virtual staining technology through cloud or on-premises deployment models. Revenue is generated through software licensing and subscription arrangements for access to the virtual staining platform, with deployment configuration determining data processing and storage arrangements.
  2. On-Premises Hardware Systems: On-premises deployment option includes dedicated server or GPU-enabled workstation infrastructure, with Pictor Labs providing software installation packages and updates while customers manage hardware, security controls, and data backups.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

PictorLabs product offering

Product offering

Core offering

Pictor Labs offers an AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. The platform uses deep learning models trained on co-registered autofluorescence and brightfield images to generate diagnostic-quality virtual stains (H&E, IHC, special stains) from unlabeled tissue samples in minutes, preserving tissue for downstream molecular and multi-modal analysis.

Product overview

Pictor Labs offers an AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. The platform generates diagnostic-quality virtual stains (H&E, IHC, and special stains) in minutes from unlabeled tissue samples, preserving tissue for downstream molecular and multi-modal analysis. The product portfolio includes DeepStain (virtual histological staining of label-free tissue), ReStain (virtual re-staining of existing H&E images), and ClearStain (virtual H&E for molecular diagnostics workflows). Both On-Premises and Cloud deployment options are available, allowing labs to choose based on data governance requirements. All products are for Research Use Only and are not FDA cleared for clinical diagnostic use.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pictor Virtual Staining Platform AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. Generates diagnostic-quality virtual stains in minutes from unlabeled tissue samples, preserving tissue for downstream analysis.
  • DeepStain Virtual histological staining technology that transforms label-free tissue autofluorescence into rich virtual stains including H&E, IHC markers, and special stains for diverse research workflows.
  • ReStain Virtual re-staining capability that applies computational transformations to already-stained H&E tissue images, generating additional stain views (Jones, PAS, Masson's Trichrome) without physical re-staining.
  • ClearStain AI-powered virtual H&E solution for molecular diagnostics workflows. Generates virtual H&E images directly from unstained tissue slides, enabling real-time tissue visualization and annotation for downstream molecular testing.
  • On-Premises Deployment Local deployment model where virtual staining runs within the customer's own infrastructure using NVIDIA DGX Spark hardware for high-performance AI inference, supporting data privacy requirements and institutional IT security policies.
  • Cloud Deployment Cloud-hosted deployment model managed by Pictor Labs offering elastic processing capacity, no local GPU hardware requirement, and centralized access for distributed research workflows.

Quantifiable outcome

  • 99-100% visual comparability to traditional chemically stained slides
  • +3 more outcomes

Companies that use PictorLabs

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles4 records

PictorLabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

PictorLabs partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and strategic.

  • NVIDIAcoreTechnology or Integration · 1 March 2026Technology partnership providing NVIDIA DGX Spark hardware for on-premises AI staining system, enabling high-performance inference for virtual staining tools deployed within pathology labs.
  • Leica BiosystemsmajorStrategic or Co-development Partner · 1 January 2024Collaborative research partnership at SITC 2024 demonstrating multi-modal spatial analysis of classic Hodgkin lymphoma microenvironment utilizing multiplex immunofluorescence and virtual staining. Combines Leica Biosystems' imaging capabilities with Pictor Labs' virtual staining technology for cancer research applications.
  • University of MarylandmajorStrategic or Co-development Partner · 1 January 2024Research collaboration for multi-modal spatial analysis of classic Hodgkin lymphoma microenvironment and tumor microenvironment analysis in cancer research. Also collaborated on AI-based computational H&E staining for lymphoma diagnosis study presented at USCAP 2024.
  • Johns HopkinsmajorStrategic or Co-development Partner · 1 January 2024Collaborative study at USCAP 2024 comparing AI computational H&E staining to chemical staining for lymphoma diagnosis, evaluating alignment between virtual and traditional stains while maintaining pathologist-led interpretation.
  • UCLAmajorStrategic or Co-development Partner · 1 January 2024Collaborative study at USCAP 2024 comparing AI computational H&E staining to chemical staining for lymphoma diagnosis, contributing to validation of virtual staining technology for hematopathology research.
  • NanoStringmajorStrategic or Co-development Partner · 1 January 2023Collaborative research presented at AACR 2023 on virtual staining-enabled morphological and spatial transcriptomic analysis of malignant B cells and the tumor microenvironment. Combines Pictor Labs' virtual staining with NanoString's spatial biology platform for advanced tissue analysis.
  • Charles RivermajorStrategic or Co-development PartnerResearch collaboration for AI-driven virtual staining generating H&E and Fluoro-Jade B images from unstained brain sections, streamlining neuronal degeneration assessment in nonclinical neurotoxicity studies (kainic acid rat model).
  • HamamatsustrategicTechnology or IntegrationScanner platform compatibility partnership ensuring Pictor virtual staining integrates with Hamamatsu digital pathology scanners for seamless workflow incorporation.
  • ProsciastrategicTechnology or IntegrationScanner platform compatibility partnership ensuring Pictor virtual staining integrates with Proscia digital pathology platform for seamless workflow incorporation.
  • GrundiumstrategicTechnology or IntegrationScanner platform compatibility partnership ensuring Pictor virtual staining integrates with Grundium whole slide imaging systems for seamless workflow incorporation.
  • pramanastrategicTechnology or IntegrationDigital pathology partnership ensuring Pictor virtual staining integrates with pramana imaging solutions for seamless workflow incorporation.
  • PredxBiostrategicTechnology or IntegrationDigital pathology partnership ensuring Pictor virtual staining integrates with PredxBio spatial biology solutions for multi-modal tissue analysis workflows.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

PictorLabs competitors and assessment

Company assessment

Direct peers

  • PathAI: Boston-based AI pathology company developing deep-learning models for diagnostic and drug-development applications across biopharma and clinical labs. Direct competitor for biopharma and CRO research budgets and for clinical pathology AI deployment.
  • Paige: AI pathology company with FDA-cleared products for prostate and breast cancer, serving biopharma, hospitals, and reference labs. Comparable in targeting biopharma and clinical pathology customers, with a head start in FDA-cleared diagnostics.
  • Owkin: AI-biopharma company with a pathology AI platform used for spatial biology, biomarker discovery, and clinical research, including federated-learning deployment. Comparable in combining AI pathology with biopharma R&D workflows.
  • Ibex Medical Analytics: Israel-based AI pathology company with multiple CE-IVD and FDA-cleared products deployed across hospital and diagnostic-lab networks. Direct competitor for clinical pathology decision-support deployments and partnerships with scanning platforms.

Emerging players

  • Aiosyn: Netherlands-based AI pathology startup focused on kidney and prostate pathology algorithms for research and clinical use. Comparable in using deep learning to generate diagnostic-quality outputs from pathology images, but narrower in tissue type coverage.
  • Deep Bio: South Korea-based AI pathology company offering deep-learning cancer diagnostic models integrated with major scanner platforms. Comparable in targeting digital pathology workflows and partnering with scanner OEMs, but focused primarily on prostate cancer diagnosis.
  • Nucleai: Israel-based spatial biology AI company applying deep learning to multiplex tissue imaging for biopharma and clinical research. Comparable in serving the spatial-biology and multi-modal tissue analysis segment of the market, particularly biopharma biomarker discovery.

Broad incumbents

  • Proscia: Digital pathology platform company offering Concentriq image management, AI integrations, and computational pathology workflows, including a partnership with Pictor Labs. Comparable as a digital pathology ecosystem player and channel partner, but broader in scope (platform vs. specific staining AI).
  • Hamamatsu Photonics: Japanese manufacturer of whole-slide imaging scanners and a long-standing incumbent in digital pathology hardware. Both a Pictor integration partner and a potential competitive threat if scanner OEMs embed native virtual-staining capabilities.
  • Leica Biosystems: Danaher-owned pathology instruments, staining reagents, and imaging business with broad clinical pathology footprint. Both a Pictor research partner and a potential competitor given internal pathology AI and reagent capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

PictorLabs social profiles

Digital presence

PictorLabs compliance and trust

Trust signal

Compliance1 record

PictorLabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PictorLabs leadership team

Management profile

Number of profiles

Profiles12 records

PictorLabs funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PictorLabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PictorLabs

What does PictorLabs do?

Pictor Labs offers an AI-powered virtual staining platform that replaces chemical tissue staining with rapid, computational alternatives. The platform uses deep learning models trained on co-registered autofluorescence and brightfield images to generate diagnostic-quality virtual stains (H&E, IHC, special stains) from unlabeled tissue samples in minutes, preserving tissue for downstream molecular and multi-modal analysis.

Is PictorLabs a public or private company?

PictorLabs is a private company. It is classified as venture growth investor backed and is currently operating.

When was PictorLabs founded?

PictorLabs was founded in 2019. It employs 11 to 50 people.

Where is PictorLabs based?

PictorLabs is headquartered in Los Angeles, United States, in the North America region.

How does PictorLabs make money?

Two revenue lines are on record. Virtual Staining Software Licenses/Subscriptions are the primary driver. The others are on-Premises Hardware Systems.

Who are PictorLabs's main competitors?

Direct peers on record are PathAI, Paige, Owkin and Ibex Medical Analytics. Emerging players are Aiosyn, Deep Bio and Nucleai. Broad incumbents are Proscia, Hamamatsu Photonics and Leica Biosystems.

Does PictorLabs have an API?

No public API is recorded for PictorLabs.

What industry is PictorLabs in?

PictorLabs's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswirePictor Labs' ClearStain™ Virtual H&E Now Available in Techcyte Fusion® AP for Molecular Tissue SelectionPictor Labs' ClearStain virtual H&E is now integrated into Techcyte Fusion AP, allowing pathologists to annotate unstained tissue sections for molecular extraction. The integration uses a proprietary algorithm to generate a virtual H&E from a brightfield scan, preserving the physical section for downstream work. It is available separately via Cloud or On-Prem deployment.DrugdiscoverytrendsPictor Labs’s new AI-powered ClearStainPictor Labs announced ClearStain, an AI-powered virtual staining technology, on Thursday. The tool generates virtual H&E images from unstained slides, achieving 99-100% visual comparability to traditional stains. It will debut at SITC 2025 on Nov. 5-9.PR NewswirePictor Labs Expands AI Pathology Portfolio with Launch of ClearStain™ for Digital Sequencing WorkflowsPictor Labs announced the launch of ClearStain™, an AI-powered virtual staining solution that generates H&E images directly from unstained slides, enabling real-time visualization and annotation of tissue for molecular diagnostics workflows. The technology demonstrated 99-100% visual comparability to traditional chemical staining in pathologist reviews while preserving tissue for downstream assays and reducing sequencing failure rates. The product debut at SITC 2025 positions Pictor Labs to expand its presence in the growing digital pathology and molecular diagnostics market, bridging histology with precision medicine.DrugdiscoverytrendsProscia adds virtual staining to Concentriq via Pictor LabsProscia will add virtual H&E, IHC, and special stains to its Concentriq platform using Pictor Labs' AI technology. The firms plan research use now, with clinical deployment contingent on lab validation. Pictor Labs' virtual stains were found visually comparable to chemical stains in independent evaluations.TracxnTop Companies in Digital Pathology Platforms (Jul, 2025)This article presents a list of top startups in the digital pathology platforms sector as of July 2025, highlighting companies such as Deciphex, Pictor Labs, PathAI, and Viz.ai. It details their founding years, locations, funding stages, and key investors, noting that several founders are alumni of prestigious universities like Stanford and Harvard. The report serves as an industry overview rather than covering a specific corporate event or transaction.PR NewswirePictorLabs and Hamamatsu Photonics announce strategic partnership to explore virtual staining technologyPictorLabs and Hamamatsu Photonics announced a strategic partnership to develop AI-powered virtual staining applications for routine laboratory use. The collaboration aims to streamline workflows and accelerate enterprise-scale digital pathology adoption. Both companies highlighted the potential to reduce tissue consumption and improve histopathology outcomes.MorningstarPictorLabs and Hamamatsu Photonics announce strategic partnership to explore virtual staining technologyPictorLabs and Hamamatsu Photonics announced a strategic partnership to develop applications for virtual staining in routine laboratory practices. PictorLabs' AI-powered technology eliminates toxic reagents and reduces turnaround times, while Hamamatsu's NanoZoomer systems provide whole slide imaging. The collaboration aims to streamline workflows and accelerate enterprise-scale digital pathology adoption.Pulse 2.0PictorLabs: UCLA Virtual Staining Technology Spin Out Secures $30 Million (Series B)PictorLabs, a UCLA spinout, closed a $30 million Series B round led by Insight Partners with M Ventures participating. The funding will support advancing its AI-based virtual staining technology, which replaces toxic reagents and cuts turnaround times from hours to minutes. The company aims to expand market reach and accelerate adoption in clinical and research settings.UCLA Samueli School of Engineering. Engineer Change.Pictor Labs Secures $30 Million to Advance AI-Driven Virtual Tissue StainingPictor Labs, a UCLA spin-off founded in 2019 by Dr. Aydogan Ozcan and Dr. Yair Rivenson, closed a $30 million Series B round led by Insight Partners with participation from M Ventures, Merck's corporate venture capital arm. The company's AI-driven virtual tissue staining technology generates digitally stained images from label-free tissue data, replacing traditional chemical staining. Funds will support scaling and commercialization.